Mounjaro denials: what the review data shows
Independent reviewers have decided 152 published cases where an insurer denied Mounjaro — and they overturned the insurer 67.1% of the time. A denial for Mounjaro is a starting position, not a final answer.
By condition
| Condition | Decisions | Overturned |
|---|---|---|
| Type 2 Diabetes | 34 | 76.5% |
| Obesity | 30 | 36.7% |
| Type 2 Diabetes Mellitus | 29 | 89.7% |
Why plans deny Mounjaro — and how appeals win
Mounjaro (tirzepatide) is FDA-approved for: type 2 diabetes. Denials that treat an on-label prescription as unproven or cosmetic are the ones reviewers reverse most readily.
Indication mismatch — the defining Mounjaro denial
Mounjaro is approved for type 2 diabetes. The same molecule, tirzepatide, is approved for weight management under the name Zepbound. Plans deny Mounjaro hard when the diagnosis on the claim is obesity rather than diabetes — and the published review outcomes show off-label weight-loss requests fare far worse than diabetes requests. If weight management is the goal, the on-label route is Zepbound, and prescriptions written that way put you on much stronger appeal footing.
“Try metformin first” step therapy
For type 2 diabetes, formularies typically require metformin and often a second agent before a GLP-1 class drug. Denials cite missing documentation of those trials more often than any clinical judgment about you.
A1C and diagnosis documentation
Approvals lean on chart-documented A1C values and a coded type 2 diabetes diagnosis. Prediabetes-coded requests are routinely denied — and the published record shows reviewers usually side with plans there.
Diabetes step-therapy requirements yield to documented failure or intolerance of preferred agents. Have your prescriber submit a step-therapy exception citing specific prior trials rather than re-arguing medical necessity from scratch.
What winning Mounjaro appeals argue
- If you have type 2 diabetes, make the record show it plainly: diagnosis codes, A1C history, current regimen, and what prior agents failed to control.
- Document metformin (and other prior-agent) trials — doses, duration, outcome, side effects — to close out the step-therapy rationale.
- If the prescription is really for weight management without diabetes, talk to your prescriber about the on-label tirzepatide product; appeals for on-label use win dramatically more often.
- For continuation denials: prior authorization already granted plus documented clinical benefit is a strong basis — plans need a reason to un-approve working therapy.
The published record backs the effort: 152 external-review decisions on Mounjaro denials, 67.1% overturned. For the full class-wide picture — cross-indication strategy, exclusion language, and the record for every GLP-1 drug — see the GLP-1 denial appeal guide.
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Mounjarowhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY